Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash from Financing Activities (2016 - 2026)

Summit Therapeutics filings provide 13 years of Cash from Financing Activities readings, the most recent being $3.8 million for Q1 2026.

  • Quarterly Cash from Financing Activities fell 50.54% to $3.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $613.7 million through Mar 2026, up 57.99% year-over-year, with the annual reading at $617.5 million for FY2025, 61.99% up from the prior year.
  • Cash from Financing Activities hit $3.8 million in Q1 2026 for Summit Therapeutics, down from $573.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $573.8 million in Q4 2025 and bottomed at -$23.6 million in Q4 2024.
  • Average Cash from Financing Activities over 5 years is $106.8 million, with a median of $16.4 million recorded in 2022.
  • Peak annual rise in Cash from Financing Activities hit 250365.0% in 2024, while the deepest fall reached 477.67% in 2024.
  • Summit Therapeutics' Cash from Financing Activities stood at $520.1 million in 2022, then plummeted by 98.8% to $6.3 million in 2023, then crashed by 477.67% to -$23.6 million in 2024, then soared by 2530.21% to $573.8 million in 2025, then plummeted by 99.34% to $3.8 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Cash from Financing Activities are $3.8 million (Q1 2026), $573.8 million (Q4 2025), and $33.8 million (Q3 2025).